| Datum | Zeit | Quelle | Überschrift | Symbol | Firma |
| 15/05/2024 | 15h29 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 10/05/2024 | 23h27 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 08/03/2024 | 22h49 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/03/2024 | 22h40 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/03/2024 | 13h35 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/03/2024 | 02h23 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 29/02/2024 | 22h44 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 29/02/2024 | 14h09 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 14/02/2024 | 23h09 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 13/02/2024 | 21h53 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 13/02/2024 | 14h50 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/02/2024 | 19h38 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 09/02/2024 | 11h45 | PR Newswire (US) | Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 07/02/2024 | 15h15 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 06/02/2024 | 23h09 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/02/2024 | 11h45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 26/01/2024 | 17h49 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 26/01/2024 | 11h45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 19/01/2024 | 11h45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 18/01/2024 | 12h56 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 18/01/2024 | 12h50 | GlobeNewswire Inc. | Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 16/01/2024 | 13h00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/01/2024 | 11h45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 09/01/2024 | 23h01 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 09/01/2024 | 23h00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 05/01/2024 | 11h45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 23/12/2023 | 01h00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 22/12/2023 | 23h15 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 20/12/2023 | 22h34 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 18/12/2023 | 11h45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |